Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879812 | 0.99 | FAAH (0.40) | FAAHCCR8HRH2KDM4ESCN9A | |
| SCHEMBL7882171 | 0.91 | HRH3 (0.38) | HRH3KDM4EHTR3ASCN9A | |
| SCHEMBL7881044 | 0.90 | SCN9A (0.38) | HRH3KDM4EHTR3ASCN9A | |
| SCHEMBL7881375 | 0.89 | FAAH (0.41) | FAAHCCR8HRH2HRH3KDM4E | |
| SCHEMBL7884249 | 0.88 | FAAH (0.42) | FAAHCCR8KDM4E | |
| SCHEMBL7881199 | 0.87 | DYRK1A (0.36) | SCN9A | |
| SCHEMBL7877894 | 0.87 | RHEB (0.36) | — | |
| SCHEMBL7881083 | 0.86 | FAAH (0.42) | FAAHCCR8HRH2HRH3KDM4E | |
| SCHEMBL7877896 | 0.86 | TLR7 (0.35) | FAAHSCN9A | |
| SCHEMBL7877751 | 0.86 | MEN1 (0.39) | KDM4EHTR3ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |